Printer Friendly

IVAX AGREES TO CEASE SALE OF LOOK-ALIKE GENERIC

 IVAX AGREES TO CEASE SALE OF LOOK-ALIKE GENERIC
 CHICAGO, Sept. 21 /PRNewswire/ -- IVAX Corp. (AMEX: IVX) has agreed


to cease distribution and sale of a "look-alike" generic verapamil HCl tablet in settlement of a lawsuit filed by Searle alleging that the product infringed upon the trade dress of its Calan SR verapamil 240 mg tablet.
 The agreement came in response to a complaint filed by Searle in Federal District Court in New Jersey on Sept. 4, 1992, asking for a order to stop IVAX and its subsidiaries from selling a generic calcium channel blocker in a tablet having a similar shape and color to that of Calan SR.
 Based on the agreement reached, IVAX will terminate all further U.S. sales and distribution of its 240 mg verapamil product using the color yellow, and will destroy all promotional material in its possession displaying the yellow 240 mg verapamil tablets. IVAX has provided Searle with a white verapamil tablet that it will begin producing immediately. Searle will withdraw its complaint following IVAX's compliance with the terms of the settlement.
 "Our aim was to protect our valuable trade dress rights in the distinctive color and shape of our 240 mg tablet and to protect consumers from any confusion relating to the two products," said Robert Bogomolny, Searle vice president and general counsel. "We are pleased that IVAX was willing to settle this matter without forcing us to further pursue the litigation."
 Searle is a research-based company that develops, manufactures and markets prescription pharmaceuticals worldwide. It is a wholly owned subsidiary of Monsanto (NYSE: MTC).
 -0- 9/21/92
 /CONTACT: Kim Piekos, 708-470-6716, or Jack Domeischel, 708-470-6720, both for Searle/
 (IVX MTC) CO: IVAX Corp.; Searle ST: Illinois IN: MTC SU:


PS -- NY067 -- 6439 09/21/92 14:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 21, 1992
Words:297
Previous Article:LTV BOARD ELECTS NEW CORPORATE OFFICERS
Next Article:ACCOUNTANTS OVERLOAD EXPANDS REGIONAL OPERATIONS; 1992 THIRD QUARTER REVENUES UP 18 PERCENT TO DATE VS. 1991
Topics:


Related Articles
IVAX AND KNOLL ANNOUNCED SETTLEMENT OF VERAPAMIL LITIGATION
IVAX ANNOUNCES SETTLEMENT OF VERAPAMIL LITIGATION
HOECHST MARION ROUSSEL RECEIVES FAVORABLE DECISION IN SELDANE PATENT SUIT
Bergen Brunswig and IVAX Sign $3.2 Billion Definitive Merger Agreement
IVAX Granted Summary Judgement In Terfenadine Patent Suit
IVAX Corporation Settles Litigation With Abbott Laboratories
Zacks.com Featured Expert Issues Recommendations On: IVX, WPI, BMY, and LLY.
DRUG MERGER SET : ANNOUNCED DEAL OF WHOLESALER BERGEN BRUNSWIG, MAKER IVAX SENDS COMPANIES' STOCKS TUMBLING.
Forest Laboratories and Lundbeck enter into settlement agreement with Alphapharm related to Lexapro patent litigation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters